Subjects (n Å 312) received either the human diploid cell rabies vaccine (HDCV) or the purified Vero cell rabies vaccine (PVRV) according to either two-injection (days 0 and 28) or three-injection (days 0, 7, and 28) primary regimens. They received a booster injection at 1 year. Rabies antibody levels were measured after the primary series and the booster and then each year for the next 10 years. The results confirm the superior long-term immunogenicity of the three-injection over the two-injection protocol. HDCV and PVRV in three doses were equally immunogenic. A booster injection at 1 year provides long-term seroconversion (titer §0.5 IU/mL). Antibody titers 2 weeks after the 1-year booster allowed prediction of long-term immunity. Good responders, with titers §30 IU/mL, were protected for at least 10 years. An algorithm for differentiation between good responders and poor responders with respect to vaccine booster strategies is proposed.
Preexposure rabies vaccination allows persons who may be the data from the present study [16] demonstrated that the three-dose schedule is more immunogenic than two injections later exposed to rabies virus to be protected by only two postexposure doses of vaccine. A three-dose preexposure series is the given on days 0 and 28, included for comparative purposes. ln addition, our preliminary analysis confirmed the importance of standard one recommended by the World Health Organization (WHO) [1] , but two doses were recommended in France and the booster injection at 1 year in maintaining immunity [16] . For high-risk groups at continuous exposure to rabies, such in the United Kingdom [2] . Since the development of cellculture vaccines, numerous efficacy and safety studies have as workers in diagnostic and research laboratories, the recommendation of all health authorities is rabies antibody measuredetermined the most efficient protocol to use for the primary series of preexposure vaccination [3 -5] . Residual immunity 1 ment every 6 months, by use of the rapid fluorescent focus inhibition test (RFFIT), to verify that protective levels (neutralyear after the completion of the primary series also has been studied, but to a lesser extent [6, 7] . In contrast, few reports ization at a 1:5 dilution [13] or at a titer of §0.5 IU/mL [1, 17] ) are maintained. For other groups at risk, such as veterinarians or on the persistence of immunity have been published [8, 9] , and the schedule of boosters thus far proposed is based on travelers to areas in which rabies is enzootic, the frequency of boosters when RFFIT testing is unavailable has been deterextrapolation. The first cell-culture rabies vaccine, the human diploid cell vaccine (HDCV), was introduced in 1975 and has mined arbitrarily; recommendations vary from once yearly to once every 3 years [1, 13, 18] . The risk of hypersensitivity become the reference standard [4, 10 -13] . Studies of the efficacy of a vaccine cultured on Vero cells (the purified Vero cell reactions to frequent HDCV boosters [13], reluctance to have frequent blood sampling, and the limited availability of RFFITrabies vaccine, PVRV) were initiated in 1983 [14, 15] . This vaccine is currently licensed in ú40 countries, and ú12 million equipped laboratories and skilled personnel warrant a more experimentally based recommendation for booster schedules. doses already have been distributed worldwide.
The Centers for Disease Control and Prevention (CDC) [13] The goals of the present trial, which was prospective, comparative, and done under field conditions, were thus to confirm and WHO [1] recommend a primary series of preexposure rabies vaccination that consists of three intramuscular injecthe superior long-term immunogenicity results (up to 10 years) of the three-injection protocol over the abbreviated, two-injections on days 0, 7, and 28. The lyophilized vaccine reconstituted in its diluent was adminisage and GMT (data not shown).
tered by the intramuscular route into the deltoid in a total volume
The average age of those subjects who were lost to follow- jects who were lost to follow-up or remained in the study was 2. The evolution of the SCR differed significantly between groups conversion of a cohort was expressed as the seroconversion rate (P õ .001). The SCR decreased more rapidly for the groups that (SCR) . A secondary quantitative evaluation criterion, the seroconversion level, was the geometric mean titer (GMT).
received the two-than for those that received the three-injection A subject whose antibody level fell below 0.5 IU/mL (seronegaprotocol (P õ .001) and for those vaccinated with PVRV than for tive subject) received a booster the following year and had a blood those vaccinated with HDCV (P Å .006). However, no significant sample drawn 14 days later and then each following year until the difference was observed between groups vaccinated with either end of the study (last sample taken at year 10). A subject whose PVRV or HDCV under the three-injection protocol. This interacantibody level remained §0.5 IU/mL for the entire study period tion between vaccine (PVRV or HDCV) and injection protocol (seroconverted subject) received a booster at the completion of the (two or three injections) effects led to the least satisfactory results 10-year period (B10), and a blood sample was taken 14 days later.
in the PVRV 2 group. If the results for the other 3 groups are
All boosters (except B1) used the PVRV vaccine (lot X0155, 5.5 considered alone, no significant difference in the evolution of IU/dose).
SCR is observed. Only 3 subjects who received either vaccine
Analysis. The analysis of the evolution of SCR from day 379 to year 10 used the actuarial method, an event being a titer that according to the three-injection protocol became seronegative, falls below 0.5 IU/mL. Data from subjects lost to follow-up were all of them between day 379 and year 3; the other 44 had received analyzed as censured data. Once the actuarial curves were calcuthe two-injection protocol. Considering the results of the subjects who received either Study population. The number of subjects included in each group and the evolution of their number over the 10-year period vaccine according to the three-injection protocol, the following predictive information can be drawn. Qualitatively, a titer of a significant booster effect: GMT of 38.9 IU/mL for HDCV and 30.7 IU/mL for PVRV (P Å .02). There was also an effect 30 IU/mL on day 379, that is, 2 weeks after the 1-year booster dose, corresponded to a positive predictive value of 100% and of dosage: GMT of 41.0 IU/mL for the three-injection protocol and 28.2 IU/mL for the abbreviated two-injection protocol (P a negative predictive value of 18% for remaining seroconverted at 10 years. Quantitatively, titers obtained on day 379 correlated õ .001). The 3 seronegative subjects, vaccinated with the three-injection significantly with those measured on each of the next 10 years (.66 £ r £ .81). The expected titer values can be calculated protocol, received a booster injection the year they became seronegative and had their titers measured 14 days thereafter. They by use of a linear regression equation of the log of the titer of the year (y) against the log of the titer on day 379 (x). For seroconverted again but with titers at low levels, dramatically lower than those obtained after the primary series or after B1. example, as determined by this linear regression analysis, the value of the antibody titer at year 10 as a function of the titer at day 379 can be calculated as y Å 0.976x 0 0.612. Discussion Booster effect at 10 years. The GMTs for the HDCV 3 and PVRV 2 groups after B10 were not significantly different
The WHO-recommended three-injection protocol [1] with either PVRV or HDCV gave superior immunogenicity results from those at day 379. In contrast, post-booster GMTs in the HDCV 2 and PVRV 3 groups were significantly lower than over the abbreviated two-injection regimen formerly used in France, throughout the 10-year follow-up. Subjects in the their day 379 values (P Å .02 and P Å .001, respectively).
A significant difference between the 4 groups in post-booster PVRV 2 group showed a more rapid decrease in their SCR values over time than did the subjects in the HDCV 2 group. GMT values (P Å .001) was observed. ln particular, there was Thus, an interaction between the number of injections and the However, the design of this study was retrospective and studied the influence of the Peace Corps volunteers' vaccination status particular rabies vaccine that was given explains why the PVRV 2 group had the poorest immunogenicity persistence of in subjects who received both pre-and postexposure vaccination regimens by different routes of administration (i.e., intrathe 4 groups. The second important finding of this study is that if subjects are given a series of three primary immunizations muscular or intradermal administration). Another retrospective study of postexposure vaccination gathered data for up to 6 and a booster at 1 year, measurement of their antibody responses 14 days after the booster (day 379) is predictive of years [20] . All other published studies had a follow-up period of õ3 years [6 -8] . The immunogenicity resulting from the persistent immunity over a 10-year period and allows an appropriate schedule of subsequent boosters.
primary vaccination series in our study, as well as the effect of a booster given 1 year later (day 42 to day 379), were The present study is the first prospective study of the persistence of immunogenicity for up to 10 years after preexposure discussed in detail in an intermediate, 5-year analysis [16] . Subjects lost to follow-up form a bias risk. An acceptable rabies vaccination. Briggs and Schwenke [9] studied the persistence of rabies vaccine immunogenicity over a 9-year period.
solution was to consider them as censored data, with the hy- pothesis that the immunogenicity of vaccination (for any of differ according to their prior responses. As frequent booster doses in good responders are unnecessary and may even be the groups) was identical between subjects lost to follow-up and those at year 10 who completed the study, as had been counterproductive, a single dose may be sufficient for serologically confirmed good responders, instead of the two-dose found to be the case between day 42 and day 379.
The three-injection protocol (HDCV 3 and PVRV 3), folschedule (days 0 and 3) currently recommended [1, 13] . This single-dose postexposure booster schedule should be further lowed by a booster dose at 1 year, maintained seroconversion up to 10 years in at least 96% of subjects, with a GMT, for substantiated before definite recommendations are made. An algorithm of the possible strategies, which may be moduexample, of 12.6 IU/mL at year 3, 10.6 IU/mL at year 5, and 8.8 IU/mL at year 10. An important decrease was observed lated as a function of the risk of exposure and the availability of a standardized RFFIT, is proposed schematically in figure during the first year after B1. At the end of the 10-year period, a booster injection reestablished the GMT to its level at day 3. It can be integrated into the recommendations that have already been put forward [1, 13, 18] for preexposure rabies 379.
A return to seronegative status may develop in some subjects vaccination and will be the subject of a future cost-benefit analysis. within the first 3 years after the 1-year booster. The titer on day 379 (14 days after B1) is predictive of the persistence of A preexposure rabies immunization regimen of only four doses on days 0, 7, 28, and 365, instead of the 7 or 12 doses antibody at a titer of ú0.5 or õ0.5 IU/mL. A titer of §30 IU/ mL (75% of vaccinated subjects) corresponded, with a nearly 100% probability, to being still seroconverted at year 10 and with a probability of at least 97.5% of having a titer of §2 IU/mL. A value of õ30 IU/mL correlated with an 18% probability of having a titer õ0.5 IU/mL in the 3 years following B1. This subset of seronegative subjects may be qualified as poor responders because their response to B1 is significantly lower than that of the other subjects. Poor responders to rabies vaccines have already been described [21] . After their titers fell to õ0.5 IU/mL, a booster injection seroconverted these subjects, but with a significantly lower amplitude than that observed after the initial B1. One year later, the titers were again low, and after 2 years, certain subjects became seronegative once again.
According to our data, poor responders can be identified by their day 379 titer being õ30 IU/mL. The strategy of serologic testing and the schedule of boosters must be adapted specifically to subjects who fall into this category. booster on day 365), the therapeutic strategy chosen should
